Summary

Persistence Market Research has recently released a comprehensive report on the worldwide market for PET radioactive tracers. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• PET Radioactive Tracers Market Size (2025E): USD 1,069.8 Million
• Projected Market Value (2032F): USD 1,706.7 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 6.9%

PET Radioactive Tracers Market - Report Scope:

PET radioactive tracers play a critical role in molecular imaging, enabling visualization of biological functions at the cellular and molecular levels. These tracers are primarily used in positron emission tomography (PET) scans for detecting cancer, neurological disorders, cardiovascular diseases, and infections. The market serves hospitals, diagnostic imaging centers, and research institutions, offering a variety of isotopes such as Fluorine-18, Carbon-11, Gallium-68, and others. Market growth is driven by increasing demand for accurate diagnostic tools, rising prevalence of chronic diseases, and advancements in radiopharmaceutical development that enhance the specificity and sensitivity of imaging techniques.

Market Growth Drivers:

The global PET radioactive tracers market is propelled by several key factors, including the rising incidence of cancer and neurodegenerative diseases that require early and precise diagnostic imaging. The increasing adoption of PET/CT and PET/MRI systems across healthcare settings further boosts the demand for tracers. Technological advancements in tracer synthesis and labeling techniques, along with expanding clinical applications beyond oncology—such as cardiology and neurology—support continued market expansion. Additionally, growing government investments in nuclear medicine infrastructure and favorable reimbursement policies in developed regions contribute to increased market adoption.

Market Restraints:

Despite its potential, the PET radioactive tracers market faces challenges related to high production and operational costs, short half-life of isotopes, and stringent regulatory requirements. The need for specialized cyclotron facilities for tracer production limits widespread accessibility, especially in low-resource settings. Additionally, complex logistics associated with the storage and transportation of radioactive substances pose significant barriers. Regulatory compliance for new radiopharmaceuticals can be time-consuming and costly, slowing down product approvals and market entry for emerging players.

Market Opportunities:

The PET radioactive tracers market presents substantial growth opportunities driven by research innovations, strategic collaborations, and geographical expansion. Development of novel tracers targeting specific molecular markers opens new avenues in precision medicine and companion diagnostics. The emergence of theranostics—combining diagnostics with therapy—offers an integrated approach to patient care and strengthens the role of PET tracers in treatment planning. Expansion of radiopharmacy networks, growing awareness in emerging economies, and integration of AI in PET imaging interpretation further unlock new prospects for manufacturers and healthcare providers.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the PET radioactive tracers market globally?
• Which tracer isotopes and applications are driving adoption across healthcare and research facilities?
• How are technological innovations reshaping the development and delivery of PET tracers?
• Who are the key players contributing to the PET radioactive tracers market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global PET radioactive tracers market?

Competitive Intelligence and Business Strategy:

These companies invest in R\&D to develop new tracer molecules with enhanced imaging characteristics and clinical applicability. Collaborations with pharmaceutical companies and research institutions accelerate the development of personalized diagnostic solutions. Moreover, geographic expansion, infrastructure investments, and focus on regulatory compliance position these companies to effectively meet the increasing global demand for PET tracers.

Key Companies Profiled:

• Eli Lilly and Company
• Blue Earth Diagnostics
• Lantheus
• Siemens Healthcare Private Limited
• GE Healthcare
• Advanced Accelerator Applications (Novartis)
• University of Lowa HealthCare
• Telix Pharmaceuticals Limited
• Jubilant Radiopharma
• TRASIS
• RadioMedix Inc.
• IBA Radiopharma Solutions
• Piramal Imaging (Life Molecular Imaging)
• Cardinal Health
• DuchemBio, Co. Ltd.

PET Radioactive Tracers Market Research Segmentation:

Product:

• F-18
• Florbetapir
• Florbetaben
• Flutemetamol
• Fludeoxyglucose
• Sodium Fluoride
• Others
• C-11
• Choline
• Methionine
• Others
• Ga-68
• DOTA-TOC
• DOTATATE
• DOTANOC
• Others
• O-15
• N-13
• Cu-64

Application:

• Neurological Disorders
• Alzheimer’s Disease
• Dementia
• Others
• Cancer Diagnosis & Prognosis
• Solid Tumors
• Hematology Tumors
• Cardiac Dysfunctions
• Myocardial Infarction
• Others
• Infectious Disease Diagnosis
• Others

End User:

• Hospitals
• Speciality Diagnostic Centers
• Cancer Research Centers
• Academic & Research Institutes

Region:

• North America
• Latin America
• East Asia
• South Asia & Pacific
• Western Europe
• Eastern Europe
• Central Asia
• Russia & Belarus
• Balkan & Baltic Countries
• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. PET Scanner Installed Base Scenario
4.2. Number of PET Scans, By Country
4.3. Disease Epidemiology
4.4. Product Adoption/Usage Analysis
4.5. Regulatory Approval Pathway
4.6. Reimbursement Scenario
4.7. Technology Advancements
4.8. Good Manufacturing Practice (cGMP)
4.9. Value Chain Analysis
4.10. Quality Standards/Accreditations
4.11. PESTEL Analysis
4.12. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Oncology Spending
5.2. Forecast Factors - Relevance & Impact
5.2.1. Development of Novel Products
5.2.2. Regulatory Imposition
5.2.3. Increasing Spending on Targeted Therapies
5.2.4. Increasing Prevalence of Cancer
5.2.5. Strategic Mergers and Acquisitions among Local Players
5.2.6. Rising Awareness towards Development of Disease
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. 2021 Market Scenario
6.2. COVID-19 and Impact Analysis
6.2.1. By Product
6.2.2. By Application
6.2.3. By End User
6.2.4. By Region
7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2019–2024 and Forecast, 2025–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2019–2024
7.2. Current and Future Market Value (US$ Mn) Projections, 2025–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019–2024
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2025–2032
8.3.1. F-18
8.3.1.1. Florbetapir
8.3.1.2. Florbetaben
8.3.1.3. Flutemetamol
8.3.1.4. Fludeoxyglucose
8.3.1.5. Sodium Fluoride
8.3.1.6. Others
8.3.2. C-11
8.3.2.1. Choline
8.3.2.2. Methionine
8.3.2.3. Others
8.3.3. Ga-68
8.3.3.1. DOTA-TOC
8.3.3.2. DOTATATE
8.3.3.3. DOTANOC
8.3.3.4. Others
8.3.4. O-15
8.3.5. N-13
8.3.6. Cu-64
8.4. Market Attractiveness Analysis By End User
9. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Application, 2019–2024
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2025–2032
9.3.1. Neurological Disorders
9.3.1.1. Alzheimer’s Disease
9.3.1.2. Dementia
9.3.1.3. Others
9.3.2. Cancer Diagnosis & Prognosis
9.3.2.1. Solid Tumor
9.3.2.2. Hematology Tumor
9.3.3. Cardiac Dysfunctions
9.3.3.1. Myocardial Infarction
9.3.3.2. Others
9.3.4. Infectious disease Diagnosis
9.3.5. Others
9.4. Market Attractiveness Analysis By End User
10. Global Market Analysis 2019–2024 and Forecast 2025–2032, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By End User, 2019–2024
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2025–2032
10.3.1. Hospitals
10.3.2. Speciality Diagnostic Centers
10.3.3. Cancer Research Centers
10.3.4. Academic & Research Institutes
10.4. Market Attractiveness Analysis By End User
11. Global Market Analysis 2019–2024 and Forecast 2025–2032, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019–2024
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025–2032
11.3.1. North America
11.3.2. Latin America
11.3.3. East Asia
11.3.4. South Asia & Pacific
11.3.5. Western Europe
11.3.6. Eastern Europe
11.3.7. Central Asia
11.3.8. Russia & Belarus
11.3.9. Balkan & Baltic Countries
11.3.10. Middle East & Africa
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2019–2024 and Forecast 2025–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Product
12.3.3. By Application
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product
12.4.3. By Application
12.4.4. By End User
12.5. Key Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product
12.8.1.2.2. By Application
12.8.1.2.3. By End User
12.8.2. Canada Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product
12.8.2.2.2. By Application
12.8.2.2.3. By End User
13. Latin America Market Analysis 2019–2024 and Forecast 2025–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Argentina
13.3.1.3. Mexico
13.3.1.4. Rest of Latin America
13.3.2. By Product
13.3.3. By Application
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By Application
13.4.4. By End User
13.5. Key Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
13.8.1. Brazil Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product
13.8.1.2.2. By Application
13.8.1.2.3. By End User
13.8.2. Argentina Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product
13.8.2.2.2. By Application
13.8.2.2.3. By End User
13.8.3. Mexico Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product
13.8.3.2.2. By Application
13.8.3.2.3. By End User
14. East Asia Market Analysis 2019–2024 and Forecast 2025–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Product
14.3.3. By Application
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Application
14.4.4. By End User
14.5. Key Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
14.8.1. China Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product
14.8.1.2.2. By Application
14.8.1.2.3. By End User
14.8.2. Japan Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product
14.8.2.2.2. By Application
14.8.2.2.3. By End User
14.8.3. South Korea Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product
14.8.3.2.2. By Application
14.8.3.2.3. By End User
15. South Asia & Pacific Market Analysis 2019–2024 and Forecast 2025–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Thailand
15.3.1.4. Philippines
15.3.1.5. Malaysia
15.3.1.6. Vietnam
15.3.1.7. Rest of ASEAN
15.3.1.8. Australia & New Zealand
15.3.2. By Product
15.3.3. By Application
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By Application
15.4.4. By End User
15.5. Key Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
15.8.1. India Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product
15.8.1.2.2. By Application
15.8.1.2.3. By End User
15.8.2. Indonesia Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product
15.8.2.2.2. By Application
15.8.2.2.3. By End User
15.8.3. Thailand Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product
15.8.3.2.2. By Application
15.8.3.2.3. By End User
15.8.4. Philippines Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product
15.8.4.2.2. By Application
15.8.4.2.3. By End User
15.8.5. Malaysia Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Product
15.8.5.2.2. By Application
15.8.5.2.3. By End User
15.8.6. Vietnam Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Product
15.8.6.2.2. By Application
15.8.6.2.3. By End User
15.8.7. Australia & New Zealand Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Product
15.8.7.2.2. By Application
15.8.7.2.3. By End User
16. Western Europe Market Analysis 2019–2024 and Forecast 2025–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. France
16.3.1.3. Spain
16.3.1.4. Italy
16.3.1.5. BENELUX
16.3.1.6. Nordic Countries
16.3.1.7. United Kingdom
16.3.2. By Product
16.3.3. By Application
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Application
16.4.4. By End User
16.5. Key Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
16.8.1. Germany Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product
16.8.1.2.2. By Application
16.8.1.2.3. By End User
16.8.2. France Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product
16.8.2.2.2. By Application
16.8.2.2.3. By End User
16.8.3. Spain Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product
16.8.3.2.2. By Application
16.8.3.2.3. By End User
16.8.4. Italy Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Product
16.8.4.2.2. By Application
16.8.4.2.3. By End User
16.8.5. BENULUX Market
16.8.5.1. Introduction
16.8.5.2. Market Analysis and Forecast by Market Taxonomy
16.8.5.2.1. By Product
16.8.5.2.2. By Application
16.8.5.2.3. By End User
16.8.6. Nordic Countries Market
16.8.6.1. Introduction
16.8.6.2. Market Analysis and Forecast by Market Taxonomy
16.8.6.2.1. By Product
16.8.6.2.2. By Application
16.8.6.2.3. By End User
16.8.7. U.K. Market
16.8.7.1. Introduction
16.8.7.2. Market Analysis and Forecast by Market Taxonomy
16.8.7.2.1. By Product
16.8.7.2.2. By Application
16.8.7.2.3. By End User
17. Eastern Europe Market Analysis 2019–2024 and Forecast 2025–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
17.3.1. By Country
17.3.1.1. Poland
17.3.1.2. Hungary
17.3.1.3. Romania
17.3.1.4. Czech Republic
17.3.1.5. Rest of Eastern Europe
17.3.2. By Product
17.3.3. By Application
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Application
17.4.4. By End User
17.5. Key Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
17.8.1. Poland Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product
17.8.1.2.2. By Application
17.8.1.2.3. By End User
17.8.2. Hungary Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product
17.8.2.2.2. By Application
17.8.2.2.3. By End User
17.8.3. Romania Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product
17.8.3.2.2. By Application
17.8.3.2.3. By End User
17.8.4. Czech Republic Market
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Product
17.8.4.2.2. By Application
17.8.4.2.3. By End User
18. Central Asia Market Analysis 2019–2024 and Forecast 2025–2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
18.3.1. By Product
18.3.2. By Application
18.3.3. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Product
18.4.2. By Application
18.4.3. By End User
18.5. Key Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Players - Intensity Mapping
19. Russia & Belarus Market Analysis 2019–2024 and Forecast 2025–2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
19.3.1. By Product
19.3.2. By Application
19.3.3. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Product
19.4.2. By Application
19.4.3. By End User
19.5. Key Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Key Players - Intensity Mapping
20. Balkan & Baltic Countries Asia Market Analysis 2019–2024 and Forecast 2025–2032
20.1. Introduction
20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
20.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
20.3.1. By Product
20.3.2. By Application
20.3.3. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Product
20.4.2. By Application
20.4.3. By End User
20.5. Key Market Trends
20.6. Drivers and Restraints - Impact Analysis
20.7. Key Players - Intensity Mapping
21. Middle East and Africa (MEA) Market Analysis 2019–2024 and Forecast 2025–2032
21.1. Introduction
21.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019–2024
21.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2025–2032
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Kingdom of Saudi Arabia
21.3.1.3. Türkiye
21.3.1.4. Northern Africa
21.3.1.5. South Africa
21.3.1.6. Israel
21.3.2. By Product
21.3.3. By Application
21.3.4. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Product
21.4.3. By Application
21.4.4. By End User
21.5. Key Market Trends
21.6. Drivers and Restraints - Impact Analysis
21.7. Key Players - Intensity Mapping
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Market
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Product
21.8.1.2.2. By Application
21.8.1.2.3. By End User
21.8.2. Kingdom of Saudi Arabia Market
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Product
21.8.2.2.2. By Application
21.8.2.2.3. By End User
21.8.3. Türkiye Market
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Product
21.8.3.2.2. By Application
21.8.3.2.3. By End User
21.8.4. Northern Africa Market
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Product
21.8.4.2.2. By Application
21.8.4.2.3. By End User
21.8.5. South Africa Market
21.8.5.1. Introduction
21.8.5.2. Market Analysis and Forecast by Market Taxonomy
21.8.5.2.1. By Product
21.8.5.2.2. By Application
21.8.5.2.3. By End User
21.8.6. Israel Market
21.8.6.1. Introduction
21.8.6.2. Market Analysis and Forecast by Market Taxonomy
21.8.6.2.1. By Product
21.8.6.2.2. By Application
21.8.6.2.3. By End User
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
22.3.1. Regional footprint of Players
22.3.2. Platform Type foot print by Players
22.3.3. Channel Foot Print by Players
23. Competition Analysis
23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
23.3.1. Eli Lilly and Company
23.3.1.1. Company Overview
23.3.1.2. Product Portfolio
23.3.1.3. Sales Footprint
23.3.1.4. Key Financials
23.3.1.5. SWOT Analysis
23.3.1.6. Key Developments
23.3.1.7. Strategy Overview
23.3.1.7.1. Channel Strategy
23.3.1.7.2. Marketing Strategy
23.3.1.7.3. Product Strategy
23.3.2. Blue Earth Diagnostics
23.3.2.1. Company Overview
23.3.2.2. Product Portfolio
23.3.2.3. Sales Footprint
23.3.2.4. Key Financials
23.3.2.5. SWOT Analysis
23.3.2.6. Key Developments
23.3.2.7. Strategy Overview
23.3.2.7.1. Channel Strategy
23.3.2.7.2. Marketing Strategy
23.3.2.7.3. Product Strategy
23.3.3. Lantheus
23.3.3.1. Company Overview
23.3.3.2. Product Portfolio
23.3.3.3. Sales Footprint
23.3.3.4. Key Financials
23.3.3.5. SWOT Analysis
23.3.3.6. Key Developments
23.3.3.7. Strategy Overview
23.3.3.7.1. Channel Strategy
23.3.3.7.2. Marketing Strategy
23.3.3.7.3. Product Strategy
23.3.4. Siemens Healthcare Private Limited
23.3.4.1. Company Overview
23.3.4.2. Product Portfolio
23.3.4.3. Sales Footprint
23.3.4.4. Key Financials
23.3.4.5. SWOT Analysis
23.3.4.6. Key Developments
23.3.4.7. Strategy Overview
23.3.4.7.1. Channel Strategy
23.3.4.7.2. Marketing Strategy
23.3.4.7.3. Product Strategy
23.3.5. GE Healthcare
23.3.5.1. Company Overview
23.3.5.2. Product Portfolio
23.3.5.3. Sales Footprint
23.3.5.4. Key Financials
23.3.5.5. SWOT Analysis
23.3.5.6. Key Developments
23.3.5.7. Strategy Overview
23.3.5.7.1. Channel Strategy
23.3.5.7.2. Marketing Strategy
23.3.5.7.3. Product Strategy
23.3.6. Advanced Accelerator Applications (Novartis)
23.3.6.1. Company Overview
23.3.6.2. Product Portfolio
23.3.6.3. Sales Footprint
23.3.6.4. Key Financials
23.3.6.5. SWOT Analysis
23.3.6.6. Key Developments
23.3.6.7. Strategy Overview
23.3.6.7.1. Channel Strategy
23.3.6.7.2. Marketing Strategy
23.3.6.7.3. Product Strategy
23.3.7. University of Lowa HealthCare
23.3.7.1. Company Overview
23.3.7.2. Product Portfolio
23.3.7.3. Sales Footprint
23.3.7.4. Key Financials
23.3.7.5. SWOT Analysis
23.3.7.6. Key Developments
23.3.7.7. Strategy Overview
23.3.7.7.1. Channel Strategy
23.3.7.7.2. Marketing Strategy
23.3.7.7.3. Product Strategy
23.3.8. Telix Pharmaceuticals Limited
23.3.8.1. Company Overview
23.3.8.2. Product Portfolio
23.3.8.3. Sales Footprint
23.3.8.4. Key Financials
23.3.8.5. SWOT Analysis
23.3.8.6. Key Developments
23.3.8.7. Strategy Overview
23.3.8.7.1. Channel Strategy
23.3.8.7.2. Marketing Strategy
23.3.8.7.3. Product Strategy
23.3.9. Jubilant Radiopharma
23.3.9.1. Company Overview
23.3.9.2. Product Portfolio
23.3.9.3. Sales Footprint
23.3.9.4. Key Financials
23.3.9.5. SWOT Analysis
23.3.9.6. Key Developments
23.3.9.7. Strategy Overview
23.3.9.7.1. Channel Strategy
23.3.9.7.2. Marketing Strategy
23.3.9.7.3. Product Strategy
23.3.10. TRASIS
23.3.10.1. Company Overview
23.3.10.2. Product Portfolio
23.3.10.3. Sales Footprint
23.3.10.4. Key Financials
23.3.10.5. SWOT Analysis
23.3.10.6. Key Developments
23.3.10.7. Strategy Overview
23.3.10.7.1. Channel Strategy
23.3.10.7.2. Marketing Strategy
23.3.10.7.3. Product Strategy
23.3.11. RadioMedix Inc.
23.3.11.1. Company Overview
23.3.11.2. Product Portfolio
23.3.11.3. Sales Footprint
23.3.11.4. Key Financials
23.3.11.5. SWOT Analysis
23.3.11.6. Key Developments
23.3.11.7. Strategy Overview
23.3.11.7.1. Channel Strategy
23.3.11.7.2. Marketing Strategy
23.3.11.7.3. Product Strategy
23.3.12. IBA Radiopharma Solutions
23.3.12.1. Company Overview
23.3.12.2. Product Portfolio
23.3.12.3. Sales Footprint
23.3.12.4. Key Financials
23.3.12.5. SWOT Analysis
23.3.12.6. Key Developments
23.3.12.7. Strategy Overview
23.3.12.7.1. Channel Strategy
23.3.12.7.2. Marketing Strategy
23.3.12.7.3. Product Strategy
23.3.13. Piramal Imaging (Life Molecular Imaging)
23.3.13.1. Company Overview
23.3.13.2. Product Portfolio
23.3.13.3. Sales Footprint
23.3.13.4. Key Financials
23.3.13.5. SWOT Analysis
23.3.13.6. Key Developments
23.3.13.7. Strategy Overview
23.3.13.7.1. Channel Strategy
23.3.13.7.2. Marketing Strategy
23.3.13.7.3. Product Strategy
23.3.14. Cardinal Health
23.3.14.1. Company Overview
23.3.14.2. Product Portfolio
23.3.14.3. Sales Footprint
23.3.14.4. Key Financials
23.3.14.5. SWOT Analysis
23.3.14.6. Key Developments
23.3.14.7. Strategy Overview
23.3.14.7.1. Channel Strategy
23.3.14.7.2. Marketing Strategy
23.3.14.7.3. Product Strategy
23.3.15. DuchemBio, Co., Ltd
23.3.15.1. Company Overview
23.3.15.2. Product Portfolio
23.3.15.3. Sales Footprint
23.3.15.4. Key Financials
23.3.15.5. SWOT Analysis
23.3.15.6. Key Developments
23.3.15.7. Strategy Overview
23.3.15.7.1. Channel Strategy
23.3.15.7.2. Marketing Strategy
23.3.15.7.3. Product Strategy
24. Assumptions and Acronyms Used
25. Research Methodology